Publication:
Seroprevalence of varicella-zoster virus antibody in Thailand

dc.contributor.authorSricharoen Migasenaen_US
dc.contributor.authorSriluck Simasathienen_US
dc.contributor.authorVarunee Desakornen_US
dc.contributor.authorBenjaluck Phonraten_US
dc.contributor.authorPravan Suntharasamaien_US
dc.contributor.authorPunnee Pitisuttithamen_US
dc.contributor.authorChanchai Areeen_US
dc.contributor.authorSupa Naksrisooken_US
dc.contributor.authorLadawan Supeeranunen_US
dc.contributor.authorRudiwilai Samakosesen_US
dc.contributor.authorFrancois Meuriceen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherPramongkutklao Hospitalen_US
dc.contributor.otherGlaxosmithkline Biologicals S.A.en_US
dc.date.accessioned2018-07-04T07:53:09Z
dc.date.available2018-07-04T07:53:09Z
dc.date.issued1997-01-01en_US
dc.description.abstractObjective: To determine the seroprevalence of varicella-zoster virus antibodies in a wide age range of healthy subjects in Thailand. Design and Methods: In 1994, blood samples were collected from 559 volunteers aged 4 months to 77 years from the Bangkok area; questionnaires about socioeconomic background and history of chickenpox or herpes zoster were also completed. Serum samples were assayed for specific varicella-zoster virus (VZV) IgG antibodies using a commercial enzyme-linked immunosorbent assay kit. Results: The seroprevalence rate (61.4% overall) increased with age: less than 1 year, 10.2%; 1 to 4 years, 24.1%; 5 to 9 years, 62.5%; 10 to 14 years, 70.4%; 15 to 19 years, 78.9%; 20 to 29 years, 69.2%; 30 to 39 years, 96.1%; 40 to 49 years, 100%; and 50 years and older, 98.0%. No significant differences in the VZV antibody prevalence with respect to gender, family size, or family income were seen. There was good correlation between varicella history and seropositivity: 92.9% of subjects with a varicella history were seropositive. Conclusions: In this urban population, approximately one in three adolescents and young adults lacked natural immunity against varicella. The results suggest that vaccination programs in Thailand and probably other tropical countries should include susceptible adolescents and adults who are at high risk of developing severe varicella and resultant complications.en_US
dc.identifier.citationInternational Journal of Infectious Diseases. Vol.2, No.1 (1997), 26-30en_US
dc.identifier.doi10.1016/S1201-9712(97)90007-2en_US
dc.identifier.issn12019712en_US
dc.identifier.other2-s2.0-12644258545en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/18210
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=12644258545&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleSeroprevalence of varicella-zoster virus antibody in Thailanden_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=12644258545&origin=inwarden_US

Files

Collections